Roschier acted for the owners of Sylphar International in the sale of the company to Karo Pharma
Independent private equity firm Vendis Capital and Robin List, the founder of Sylphar, have agreed to sell all of the shares in Sylphar International NV to Karo Pharma Aktiebolag (publ), listed on Nasdaq Stockholm Mid Cap, for EUR 290 million. Roschier advised the sellers in the transaction.
Karo Pharma is to acquire the Sylphar Group for EUR 290 million on a cash and debt free basis, and a minor additional payment amounting to EUR 10 million may be paid if certain conditions are met in relation to future growth targets for the Sylphar Group. The transaction is expected to be completed during January 2022 and is subject to customary competition authority approvals.
Sylphar is a Belgium based fast-growing and digital-first platform with a proven ability to grow and internationalize brands in the consumer health and beauty markets. It offers a portfolio of leading brands in these markets mainly sold through online marketplaces, web shops and e-pharmacies. The Sylphar brands are distributed in more than 50 countries worldwide through local distribution partners and online platforms. The major markets of the company include UK, Germany, Italy, Spain and France.
Roschier’s advisory team included Ola Sandersson, Malin Leffler and Erik Persson.